ZyVersa Therapeutics Files Definitive Proxy Statement

TL;DR

ZyVersa (formerly Larkspur) filed its proxy statement. Standard stuff.

AI Summary

ZyVersa Therapeutics, Inc. filed a definitive proxy statement (DEF 14A) on September 9, 2024. The filing concerns the company's proxy materials, indicating it is a standard regulatory filing rather than a specific event like an acquisition or earnings release. The company was formerly known as Larkspur Health Acquisition Corp. until April 26, 2021.

Why It Matters

This filing is a routine regulatory requirement for public companies, providing shareholders with information for upcoming meetings and votes.

Risk Assessment

Risk Level: low — This is a routine DEF 14A filing, which typically does not introduce new risks but rather discloses information related to corporate governance and shareholder matters.

Key Players & Entities

• ZyVersa Therapeutics, Inc. (company) — Registrant
• Larkspur Health Acquisition Corp. (company) — Former company name
• 0001493152-24-035480 (filing_id) — Accession Number
• 20240909 (date) — Filing Date

FAQ

Key Financial Figures

• $15,000 — LLC will receive a fee of approximately $15,000, as well as reimbursement for certain c

Filing Documents

• formdef14a.htm (DEF 14A) — 1077KB
• proxycard_001.jpg (GRAPHIC) — 376KB
• proxycard_002.jpg (GRAPHIC) — 292KB
• 0001493152-24-035480.txt ( ) — 1998KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 31 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 33

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 41 DIRECTOR COMPENSATION 49 INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 50 DELINQUENT SECTION 16(A) REPORTS 52 HOUSEHOLDING OF PROXY MATERIALS 52 FORM 10-K INFORMATION; OTHER SEC FILINGS 52 OTHER MATTERS 52 Annex A - Amended and Restated ZyVersa Therapeutics, Inc. 2022 Omnibus Equity Incentive Plan A-1 Annex B - Form of Series A-1 Warrant B-1 Annex C - Form of Series B-1 Warrant C-1 i ZYVERSA THERAPEUTICS, INC. 2200 N. Commerce Parkway, Suite 208 Weston, Florida 33326 PROXY FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS October 29, 2024 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Who is ZyVersa Therapeutics, Inc.? ZyVersa Therapeutics, Inc. (the “Company,” “ZyVersa,” “we,” “us,” or “our”) is a clinical stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. Our mission is to develop drugs that optimize health outcomes and improve patients’ quality of life. We have two proprietary globally licensed drug development platforms, each of which was discovered by research scientists at the University of Miami, Miller School of Medicine (the “University of Miami” or “University”). These development platforms are: Cholesterol Efflux Mediator TM VAR 200 (2-hydroxypropyl-beta-cyclodextrin or “2HPβCD”) is an injectable drug in clinical development for treatment of renal diseases. VAR 200 was licensed from L&F Research LLC on December 15, 2015. L&F Research was founded by the University of Miami research scientists who discovered the use of VAR 200 for renal diseases. Inflammasome ASC Inhibitor IC 100 is a humanized monoclonal antibody in preclinical development for treatment of inflammatory conditions. IC 100 was licensed from InflamaCore, LLC on

Business

Business Combination On December 12, 2022 (the “Closing Date”), we consummated the previously announced Business Combination (as defined below) pursuant to the terms of that certain Business Combination Agreement (the “Business Combination Agreement”), by and among ZyVersa Therapeutics, Inc., a Florida corporation (“Old ZyVersa”), the representative of Old ZyVersa’s shareholders named therein (the “Securityholder Representative”), Larkspur Health Acquisition Corp., a Delaware corporation (“Larkspur”), and Larkspur Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Larkspur (“Merger Sub”). Pursuant to the terms of the Business Combination Agreement (and upon all other conditions of the Business Combination Agreement being satisfied or waived), on the Closing Date of the Business Combination and transactions contemplated thereby (the “Business Combination”), (i) Larkspur changed its name to “ZyVersa Therapeutics, Inc.”, a Delaware corporation (the “Company”) and (ii) Merger Sub merged with and into Old ZyVersa (the “Merger”), with Old ZyVersa as the surviving company in the Merger and, after giving effect to such Merger, Old ZyVersa became a wholly-owned subsidiary of the Company. Prior to the completion of the Business Combination, the Company was a shell company. Following the Business Combination, the business of Old ZyVersa is the business of the Company. The Company was incorporated in the State of Delaware on March 17, 2021 and its subsidiary, Old ZyVersa, was incorporated on March 11, 2014. Larkspur Merger Sub, Inc. was incorporated in the State of Delaware on July 13, 2022. Our principal executive offices are located at 2200 North Commerce Parkway, Suite 208, Weston, Florida 33326, and our telephone number is (754) 231-1688. Our website address is http://www.zyversa.com. The information contained on or otherwi

View Full Filing

View this DEF 14A filing on SEC EDGAR